⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21964325 | 1.00 | — | — | |
| SCHEMBL4958424 | 0.81 | — | — | |
| SCHEMBL11889595 | 0.81 | — | — | |
| SCHEMBL28384788 | 0.73 | TSHR (0.37) | — | |
| SCHEMBL19896899 | 0.70 | — | — | |
| SCHEMBL8920620 | 0.70 | — | — | |
| SCHEMBL1380121 | 0.70 | — | — | |
| SCHEMBL3965857 | 0.70 | SIRT2 (0.32) | — | |
| Hydrochloric Acid SCHEMBL3971166 | 0.69 | SIRT2 (0.31) | — | |
| SCHEMBL13967075 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12351565-B2 | Aromatic compound and preparation method therefor and use thereof | SHANGHAI ZHIGEN PHARMACEUTICAL & TECHNOLOGY CO., LTD. (CN) | 2025-07-08 | — | — | US | disclosed |
| US-20210198218-A1 | COMPOUNDS FOR THERAPEUTIC USE | DART NEUROSCIENCE LLC (US) | 2021-07-01 | — | — | US | disclosed |
| EP-3507277-B1 | HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF DISORDERS | DART NEUROSCIENCE LLC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10738018-B2 | Compounds for therapeutic use | DART NEUROSCIENCE, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3507277-A1 | HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | Dart NeuroScience LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| CN-109890798-A | HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | 达特神经科学有限公司 | 2019-06-14 | — | — | CN | disclosed |
| US-20180251435-A1 | COMPOUNDS FOR THERAPEUTIC USE | DART NEUROSCIENCE LLC (US) | 2018-09-06 | — | — | US | disclosed |
| US-9963435-B2 | Compounds for therapeutic use | DART NEUROSCIENCE, LLC (US) | 2018-05-08 | — | — | US | disclosed |
| WO-2018044896-A1 | HYDROXYNORKETAMINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | DART NEUROSCIENCE, LLC (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180057470-A1 | COMPOUNDS FOR THERAPEUTIC USE | DART NEUROSCIENCE, LLC | 2018-03-01 | — | — | US | disclosed |
| WO-2017165877-A1 | METHODS OF USING (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE IN THE TREATMENT OF DEPRESSION, ANXIETY, ANHEDONIA, SUICIDAL IDEATION, AND POST TRAUMATIC STRESS DISORDERS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017165878-A1 | CRYSTAL FORMS AND METHODS OF SYNTHESIS OF (2R, 6R)-HYDROXYNORKETAMINE AND (2S, 6S)-HYDROXYNORKETAMINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-09-28 | — | — | WO | disclosed |